Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Sequential treatment with tamoxifen and letrozole did not improve disease-free survival in postmenopausal women with early breast cancer compared to letrozole alone. Overall survival differences between letrozole and tamoxifen monotherapy were not statistically significant.
Area Of Science
- Oncology
- Endocrinology
- Clinical Trials
Background
- Letrozole improves disease-free survival over tamoxifen in postmenopausal early breast cancer.
- The efficacy of sequential tamoxifen and letrozole versus letrozole monotherapy is not established.
Purpose Of The Study
- To compare sequential tamoxifen-letrozole treatments with letrozole monotherapy for early breast cancer.
- To analyze overall survival differences between letrozole and tamoxifen monotherapy.
Main Methods
- Randomized, phase 3, double-blind trial involving 6182 postmenopausal women.
- Assignment to 5 years of tamoxifen, 5 years of letrozole, or sequential therapy (2 years one agent, 3 years the other).
- Updated analysis of monotherapy treatments in 4922 women.
Main Results
- Sequential treatments did not significantly improve disease-free survival compared to letrozole alone (HR 1.05 and 0.96).
- Higher early relapse rates observed with tamoxifen followed by letrozole.
- No statistically significant difference in overall survival between letrozole and tamoxifen monotherapy (P=0.08).
Conclusions
- Sequential letrozole and tamoxifen therapy does not enhance disease-free survival versus letrozole monotherapy.
- No significant difference in overall survival between letrozole and tamoxifen monotherapy.
- Adverse event rates were consistent with prior findings for both agents.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.